Luo Yunxiu, Huang Xiaopeng, Zhan Jiabin, Zhang Shuai
Department of Radiation Oncology, Hainan Cancer Hospital, Affiliated Cancer Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, People's Republic of China.
Department of Radiation Oncology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, 570311, Hainan Province, People's Republic of China.
Int J Gen Med. 2021 Dec 1;14:9247-9260. doi: 10.2147/IJGM.S337769. eCollection 2021.
Due to the limitations of currently available biomarkers, new biomarkers are needed to accurately predict the prognosis of patients with hepatocellular carcinoma (HCC) patients.
In this study, we screened for differentially expressed genes (DEGs) in the tumor and the adjacent tissues using the four gene expression array () of the Gene Express Omnibus (GEO) database.
Subsequently, 47 overlapping DEGs were identified in four GEO datasets, which were mostly located on chromosomes 5q and 6q, distributed in the liver and CD105-positive endothelial cells, and closely related to HCC. Function enrichment revealed 47 DEGs were related to HCC, and involved in steroid /lipid /retinol metabolism, bile secretion and p53 signalling pathway. The Kaplan-Meier plotter analysis (http://www.kmplot.com/) identified 26 and 40 genes associated with the 5-year overall survival (OS) and relapse-free survival (RFS). We found that and were independent prognostic factors for 5-year OS (=0.036) and RFS (=0.044) in HCC patients from , respectively. Clinicopathological features including BCLC stage, cirrhosis, and risk signature for predicted metastasis were used to construct and validate a nomogram for 5-year OS with C-index of 0.732 and 0.717 in the training and validation cohort, respectively. , BCLC stage and gender was independent prognostic factors for RFS which were used to build a nomogram with the C-index of 0.666 and 0.682 in the training and validation cohort, respectively.
can facilitate individualized, targeted therapy for HCC patients.
由于目前可用生物标志物的局限性，需要新的生物标志物来准确预测肝细胞癌（HCC）患者的预后。
在本研究中，我们使用基因表达综合数据库（GEO）的四个基因表达阵列筛选肿瘤组织和相邻组织中的差异表达基因（DEG）。
随后，在四个GEO数据集中鉴定出47个重叠的DEG，它们大多位于5号和6号染色体上，分布于肝脏和CD105阳性内皮细胞中，且与HCC密切相关。功能富集分析显示，47个DEG与HCC相关，参与类固醇/脂质/视黄醇代谢、胆汁分泌和p53信号通路。Kaplan-Meier绘图分析（http://www.kmplot.com/）确定了26个和40个与5年总生存期（OS）和无复发生存期（RFS）相关的基因。我们发现，[具体基因1]和[具体基因2]分别是来自[具体数据集]的HCC患者5年OS（P = 0.036）和RFS（P = 0.044）的独立预后因素。包括BCLC分期、肝硬化和预测转移的风险特征在内的临床病理特征被用于构建和验证5年OS的列线图，训练队列和验证队列中的C指数分别为0.732和0.717。[具体基因3]、BCLC分期和性别是RFS的独立预后因素，分别用于构建训练队列和验证队列中C指数为0.666和0.682的列线图。
[具体内容]可为HCC患者提供个体化的靶向治疗。
